Amneal Pharmaceuticals, Inc.
AMRXNASDAQHealthcare● Active
$13.79
+$0.04(+0.31%)
Market Cap$4.4B
P/E Ratio—
52W High$15.42
52W Low$7.07
Amneal Pharmaceuticals, Inc. (AMRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AMRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.27
Est. $0.17 · +58.8%
Revenue
$0.72B
Est. $0.72B · +0.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
AMRX reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.24 | — | — | — | $0.76B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.17 | $0.27 | +58.8% | $0.72B | $0.72B | +0.4% |
| ▲ Q1 FY2026 | Feb 27, 2026 | $0.18 | $0.21 | +16.7% | $0.81B | $0.81B | +0.9% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.13 | $0.17 | +30.8% | $0.78B | $0.81B | -2.7% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.18 | $0.25 | +38.9% | $0.72B | $0.77B | -5.7% |
| ▲ Q2 FY2025 | May 2, 2025 | $0.15 | $0.21 | +40.0% | $0.70B | $0.74B | -6.6% |
| ▼ Q1 FY2025 | Feb 28, 2025 | $0.15 | $0.12 | -20.0% | $0.73B | $0.72B | +1.0% |
| ▲ Q4 FY2024 | Nov 8, 2024 | $0.13 | $0.16 | +23.1% | $0.70B | $0.70B | +0.2% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.27
EPS Est.
$0.17
EPS Surpr.
+58.8%
Revenue
$0.72B
Q1 FY2026
Feb 27, 2026Beat
EPS Actual
$0.21
EPS Est.
$0.18
EPS Surpr.
+16.7%
Revenue
$0.81B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.17
EPS Est.
$0.13
EPS Surpr.
+30.8%
Revenue
$0.78B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.25
EPS Est.
$0.18
EPS Surpr.
+38.9%
Revenue
$0.72B
Q2 FY2025
May 2, 2025Beat
EPS Actual
$0.21
EPS Est.
$0.15
EPS Surpr.
+40.0%
Revenue
$0.70B
Q1 FY2025
Feb 28, 2025Miss
EPS Actual
$0.12
EPS Est.
$0.15
EPS Surpr.
-20.0%
Revenue
$0.73B
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
$0.16
EPS Est.
$0.13
EPS Surpr.
+23.1%
Revenue
$0.70B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.32 | $0.33 | $0.33 | 2 |
| Q3 FY2027 | $0.29 | $0.29 | $0.30 | 1 |
| Q2 FY2027 | $0.25 | $0.26 | $0.26 | 1 |
| Q1 FY2027 | $0.25 | $0.26 | $0.26 | 2 |
| Q4 FY2026 | $0.27 | $0.27 | $0.28 | 2 |
| Q3 FY2026 | $0.24 | $0.25 | $0.26 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.9B | $0.9B | $0.9B | 1 |
| Q3 FY2027 | $0.8B | $0.9B | $0.9B | 2 |
| Q2 FY2027 | $0.8B | $0.8B | $0.8B | 2 |
| Q1 FY2027 | $0.8B | $0.8B | $0.8B | 1 |
| Q4 FY2026 | $0.8B | $0.8B | $0.8B | 2 |
| Q3 FY2026 | $0.8B | $0.8B | $0.8B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +58.8% | $13.62 | $13.72 | +0.73% |
| ▲ Q1 FY2026 | Feb 27, 2026 | +16.7% | $14.49 | $13.81 | -4.69% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +30.8% | $10.43 | $10.00 | -4.12% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +38.9% | $7.96 | $8.13 | +2.14% |
| ▲ Q2 FY2025 | May 2, 2025 | +40.0% | $7.74 | $7.97 | +2.97% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -20.0% | $8.38 | $8.67 | +3.46% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +23.1% | $8.61 | $8.73 | +1.39% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +14.3% | $7.77 | $7.65 | -1.54% |
Q2 FY2026+0.73%
Report Date
May 7, 2026
EPS Beat/Miss
+58.8%
Price Before
$13.62
Price After
$13.72
Q1 FY2026-4.69%
Report Date
Feb 27, 2026
EPS Beat/Miss
+16.7%
Price Before
$14.49
Price After
$13.81
Q4 FY2025-4.12%
Report Date
Oct 30, 2025
EPS Beat/Miss
+30.8%
Price Before
$10.43
Price After
$10.00
Q3 FY2025+2.14%
Report Date
Aug 5, 2025
EPS Beat/Miss
+38.9%
Price Before
$7.96
Price After
$8.13
Q2 FY2025+2.97%
Report Date
May 2, 2025
EPS Beat/Miss
+40.0%
Price Before
$7.74
Price After
$7.97
Q1 FY2025+3.46%
Report Date
Feb 28, 2025
EPS Beat/Miss
-20.0%
Price Before
$8.38
Price After
$8.67
Q4 FY2024+1.39%
Report Date
Nov 8, 2024
EPS Beat/Miss
+23.1%
Price Before
$8.61
Price After
$8.73
Q3 FY2024-1.54%
Report Date
Aug 9, 2024
EPS Beat/Miss
+14.3%
Price Before
$7.77
Price After
$7.65
Avg Beat Reaction-0.45%
Avg Miss Reaction+3.46%
Beat Rate7 / 8 quarters
Largest Move-4.69% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AMRX ends December
Amneal Pharmaceuticals, Inc. (AMRX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.27 — beating the analyst consensus of $0.17 by +58.8%. AMRX has beaten EPS estimates for 5 consecutive quarters. The next AMRX earnings date is expected around September 1, 2026.
Each quarter, investors track AMRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AMRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AMRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AMRX earnings · 5 questionsAmneal Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. AMRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AMRX historically reports after market close (AMC).
AMRX earnings datewhen is AMRX earningsAMRX next earnings datewhen does AMRX report earningsAMRX earnings calendar
▸ Source: FMP · Amneal Pharmaceuticals, Inc. SEC filings · US GAAP · Amneal Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026